A randomized, double-blinded, placebo-controlled phase I study of ABX-1431 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2016
At a glance
- Drugs ABX 1431 (Primary)
- Indications Central pain; Epilepsy; Neurogenic inflammation; Neurological disorders
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 14 Dec 2016 According to an Abide Therapeutics media release, status changed from recruiting to completed.
- 10 May 2016 According to Abide media release, company has successfully completed dosing in this study.
- 09 Jul 2015 New trial record